EU regulators are considering withdrawing market authorizations for two hair loss and enlarged prostate treatments over ...
But in 2018, the company reached a deal with pharmaceutical manufacturer GlaxoSmithKline to tap customers’ genetic data for ...
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...
The life sciences developer acquired the site as part of a master lease agreement with seller MIT that expires in 2099.
With a drug in advanced testing for two different indications that have spawned several blockbuster drugs, could Alumis be ...
In a report released today, Peter Welford from Jefferies maintained a Buy rating on GlaxoSmithKline (GSK – Research Report), with a price ...
The once-hot Silicon Valley startup has seen its stock’s value decline 99% and is struggling to survive. That has put the ...
"I've watched and been a part of Illumina growing from a startup to one of the most important and innovative companies in the ...
Malay Mail on MSN1d
GSK’s Arexvy vaccine approved to protect older adults from respiratory syncytial virus (RSV) disease in MalaysiaGlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that Arexvy has been approved in Malaysia for respiratory ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback